Yadin Rozov Net Worth

The estimated Net Worth of Yadin Rozov is at least 206 千$ dollars as of 13 March 2023. Yadin Rozov owns over 70,000 units of Oramed Pharmaceuticals, Inc stock worth over 205,870$ and over the last 3 years Yadin sold ORMP stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Yadin Rozov ORMP stock SEC Form 4 insiders trading

Yadin has made over 1 trades of the Oramed Pharmaceuticals, Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Yadin bought 70,000 units of ORMP stock worth 141,400$ on 13 March 2023.

The largest trade Yadin's ever made was buying 70,000 units of Oramed Pharmaceuticals, Inc stock on 13 March 2023 worth over 141,400$. On average, Yadin trades about 14,000 units every 0 days since 2022. As of 13 March 2023 Yadin still owns at least 86,500 units of Oramed Pharmaceuticals, Inc stock.

You can see the complete history of Yadin Rozov stock trades at the bottom of the page.

Insiders trading at Oramed Pharmaceuticals, Inc

Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over 7,377,390$ worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth 3,583,418$ . The most active insiders traders include Miriam Kidron、Leonard Sank、Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of 97,149$. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth 19,556$.

What does Oramed Pharmaceuticals, Inc do?

oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg

Complete history of Yadin Rozov stock trades at Oramed Pharmaceuticals, Inc

Oramed Pharmaceuticals, Inc executives and stock owners

Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include:

• Nadav Kidron,
  President, Chief Executive Officer, Director
• Nadav Kidron Esq.,
  Pres, CEO & Exec. Director
• Miriam Kidron,
  Chief Scientific Officer, Director
• Joshua Hexter,
  Chief Operating and Business Officer
• Dr. Miriam Kidron Ph.D.,
  Chief Scientific Officer & Director
• Dr. Miriam Kidron,
  Chief Scientific Officer & Director
• Michael Rabinowitz,
  Chief Commercial Officer
• Joshua Hexter,
  Chief Operating & Bus. Officer
• David Silberman,
  CFO, Treasurer & Sec.
• Avraham Gabay,
  Chief Financial Officer, Treasurer, Secretary
• Kevin Rakin,
  Independent Chairman of the Board
• Leonard Sank,
  Independent Director
• Arie Mayer,
  Independent Director
• Xiaoming Gao,
  Independent Director
• Aviad Friedman,
  Independent Director
• Dr. Roy Eldor M.D., Ph.D.,
  Chief Medical Advisor & Member of the Scientific Advisory Board
• Daniel Aghion,
  Director
• Capital Management Lp Regal...,
  
• Xiaopeng Li,
  Director
• David Mark Slager,
  Director
• Harold Jacob,
  Director
• Gerald M Ostrov,
  Director
• Capital Management Lp Regals,
  10% owner
• Ronald Edward Law,
  Chief Strategy Officer
• Michael Berelowitz,
  Director
• Yifat Hen Zommer,
  CFO, Treasurer and Secretary
• Hilla Eisenberg,
  CFO, Treasurer and Secretary
• David Silberman,
  Chief Financial Officer
• Mark Daniel Hasleton,
  VP Business Development
• Michael Rabinowitz,
  Chief Commercial Officer
• Chaime Orlev,
  CFO, TREASURER AND SECRETARY
• Benjamin Shapiro,
  Director
• Michael Rabinowitz,
  Chief Commercial Officer
• Netanel Derovan,
  Chief Legal Officer
• Yadin Rozov,
  Director
• Yehuda Reznick,
  Director